Literature DB >> 8579961

Bone changes in mucopolysaccharidosis VI in cats and the effects of bone marrow transplantation: mechanical testing of long bones.

R W Norrdin1, S J Simske, S Gaarde, J D Schwardt, M A Thrall.   

Abstract

Mucopolysaccharidosis VI (MPS VI) is a genetic lysosomal storage disease in which a defect in aryl sulfatase B leads to accumulation of the glycosaminoglycan dermatan sulfate and abnormalities in the development of cartilage and bone. A feline model of this disease was used to evaluate the efficacy of bone marrow transplant (BMT) therapy. Long bones from MPS VI cats (N = 6) and MPS VI + BMT cats (N = 7) were compared with control cats (N = 11) and control + BMT cats (N = 5) in mechanical tests. Dissected femurs and tibias were subjected to three-point bending and a subgroup of tibias were tested with the mechanical response tissue analyzer (MRTA) in which vibration is used to measure tissue impedance. Cats with MPS VI had markedly decreased stiffness and strength in both bone (p < 0.01). There was no significant difference in the MPS VI + BMT group. In the tibias, there was also decreased stiffness and strength in the control + BMT group as compared to controls (p < 0.05). However, when cross-sectional area was used to normalize for bone size there was good correlation with strength in both femurs (r = 0.907, p < 0.01) and tibias (r = 0.915, p < 0.1), and there were no significant differences between groups in the modulus of elasticity. In the tibias, in which stiffness was measured by MRTA, there was significant correlation with three-point bending stiffness. These results indicate that, in cats with MPS VI, the decreases in stiffness and strength of long bones can be largely accounted for by the decrease in bone size (osteopenia) that is present.

Entities:  

Mesh:

Year:  1995        PMID: 8579961     DOI: 10.1016/8756-3282(95)00333-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs.

Authors:  Sun H Peck; Philip J M O'Donnell; Jennifer L Kang; Neil R Malhotra; George R Dodge; Maurizio Pacifici; Eileen M Shore; Mark E Haskins; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2015-09-26       Impact factor: 4.797

2.  Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI.

Authors:  Tamara Alliston
Journal:  J Pediatr Rehabil Med       Date:  2010

3.  Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs.

Authors:  Katherine Parker Ponder; John R Melniczek; Lingfei Xu; Margaret A Weil; Thomas M O'Malley; Patricia A O'Donnell; Van W Knox; Gustavo D Aguirre; Hamutal Mazrier; N Matthew Ellinwood; Meg Sleeper; Albert M Maguire; Susan W Volk; Robert L Mango; Jean Zweigle; John H Wolfe; Mark E Haskins
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

Review 4.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

Review 5.  Animal models for mucopolysaccharidosis disorders and their clinical relevance.

Authors:  Mark E Haskins
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

Review 6.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

7.  Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.

Authors:  Bianca Link; Louise Lapagesse de Camargo Pinto; Roberto Giugliani; James Edmond Wraith; Nathalie Guffon; Elke Eich; Michael Beck
Journal:  Orthop Rev (Pavia)       Date:  2010-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.